Cardiac peroxisome proliferator-activated receptor-α activation causes increased fatty acid oxidation, reducing efficiency and post-ischaemic functional loss

Cardiovascular Research

Volumn 83, Issue 3, 2009, Pages 519-526

  Hafstad, Anne D ^a   Khalid, Ahmed M ^a   Hagve, Martin ^a   Lund, Trine ^a   Larsen, Terje S ^a   Severson, David L ^b   Clarke, Kieran ^c   Berge, Rolf K ^d   Aasum, Ellen ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

Cardiac efficiency; Cardiac function; Cardiac metabolism; Fatty acid oxidation; Glucose oxidation; Ischaemia reperfusion; PPAR target genes

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TETRADECYLTHIOACETIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA FLOW; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG ACTIVITY; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; GENE EXPRESSION; GENE TARGETING; GLUCOSE BLOOD LEVEL; GLUCOSE OXIDATION; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART VENTRICLE CONTRACTILITY; HEART VENTRICLE FUNCTION; IN VIVO STUDY; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; TRANSCRIPTION INITIATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; CARDIOVASCULAR AGENTS; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; FATTY ACIDS; GENE EXPRESSION REGULATION; LIVER; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; OXIDATION-REDUCTION; OXYGEN CONSUMPTION; PPAR ALPHA; RECOVERY OF FUNCTION; RNA, MESSENGER; SULFIDES; TRIGLYCERIDES; VENTRICULAR FUNCTION;

EID: 67651121838     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp132     Document Type: Article

References (37)

1. Kelly DP. PPARs of the heart: three is a crowd. Circ Res 2003;92:482-484.
2. Barger PM, Kelly DP. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med 2000;10:238-245.
3. Finck BN. The PPAR regulatory system in cardiac physiology and disease. Cardiovasc Res 2007;73:269-277.
4. Gilde AJ, van der Lee KA, Willemsen PH, Chinetti G, van der Leij FR, van der Vusse GJ et al. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 2003;92:518-524.
5. van der Lee KA, Vork MM, De Vries JE, Willemsen PH, Glatz JF, Reneman RS et al. Long-chain fatty acid-induced changes in gene expression in neonatal cardiac myocytes. J Lipid Res 2000;41:41-47.
6. Campbell FM, Kozak R, Wagner A, Altarejos JY, Dyck JR, Belke DD et al. A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem 2002;277:4098-4103.
7. Sambandam N, Morabito D, Wagg C, Finck BN, Kelly DP, Lopaschuk GD. Chronic activation of PPARalpha is detrimental to cardiac recovery after ischemia. Am J Physiol Heart Circ Physiol 2006;290:H87-H95.
8. Watanabe K, Fujii H, Takahashi T, Kodama M, Aizawa Y, Ohta Y et al. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity. J Biol Chem 2000;275:22293-22299.
9. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002;109:121-130.
10. King KL, Young ME, Kerner J, Huang H, O'shea KM, Alexson SE et al. Diabetes or peroxisome proliferator-activated receptor alpha agonist increases mitochondrial thioesterase I activity in heart. J Lipid Res 2007;48:1511-1517.
11. Young ME, Patil S, Ying J, Depre C, Ahuja HS, Shipley GL et al. Uncoupling protein 3 transcription is regulated by peroxisome proliferator-activated receptor (alpha) in the adult rodent heart. FASEB J 2001;15:833-845.
12. Pruimboom Brees I, Haghpassand M, Royer L, Brees D, Aldinger C, Reagan W et al. A critical role for peroxisomal proliferator-activated receptor-alpha nuclear receptors in the development of cardiomyocyte degeneration and necrosis. Am J Pathol 2006;169:750-760.
13. Aasum E, Khalid AM, Gudbrandsen OA, How OJ, Berge RK, Larsen TS. Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice. J Mol Cell Cardiol 2008;44:201-209.
14. Cook WS, Yeldandi AV, Rao MS, Hashimoto T, Reddy JK. Less extrahepatic induction of fatty acid beta-oxidation enzymes by PPAR alpha. Biochem Biophys Res Commun 2000;278:250-257.
15. Aasum E, Cooper M, Severson DL, Larsen TS. Effect of BM 17.0744, a PPARalpha ligand, on the metabolism of perfused hearts from control and diabetic mice. Can J Physiol Pharmacol 2005;83:183-190.
16. Aasum E, Belke DD, Severson DL, Riemersma RA, Cooper M, Andreassen M et al. Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator. Am J Physiol Heart Circ Physiol 2002;283:H949-H957.
17. Berge RK, Skorve J, Tronstad KJ, Berge K, Gudbrandsen OA, Grav H. Metabolic effects of thia fatty acids. Curr Opin Lipidol 2002;13:295-304.
18. Madsen L, Guerre-Millo M, Flindt EN, Berge K, Tronstad KJ, Bergene E et al. Tetradecylthioacetic acid prevents high fat diet induced adiposity and insulin resistance. J Lipid Res 2002;43:742-750.
19. How OJ, Aasum E, Kunnathu S, Severson DL, Myhre ES, Larsen TS. Influence of substrate supply on cardiac efficiency, as measured by pressure-volume analysis in ex vivo mouse hearts. Am J Physiol Heart Circ Physiol 2005;288:H2979-H2985.
20. How OJ, Aasum E, Severson DL, Chan WY, Essop MF, Larsen TS. Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 2006;55:466-473.
21. Vandesompele J, De PK, Pattyn F, Poppe B, Van RN, De PA et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3: RESEARCH0034.1-0034.11.
22. Belke DD, Larsen TS, Gibbs EM, Severson DL. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab 2000;279:E1104-E1113.
23. Aasum E, Hafstad AD, Severson DL, Larsen TS. Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes 2003;52:434-441.
24. Campbell FM, Kozak R, Wagner A, Altarejos JY, Dyck JRB, Belke DD et al. A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem 2002; 277:4098-4103.
25. Raspe E, Madsen L, Lefebvre AM, Leitersdorf I, Gelman L, Peinado Onsurbe J et al. Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARalpha activation. J Lipid Res 1999;40:2099-2110.
26. Berge RK, Tronstad KJ, Berge K, Rost TH, Wergedahl H, Gudbrandsen OA et al. The metabolic syndrome and the hepatic fatty acid drainage hypothesis. Biochimie 2005;87:15-20.
27. Korvald C, Elvenes OP, Myrmel T. Myocardial substrate metabolism influences left ventricular energetics in vivo. Am J Physiol Heart Circ Physiol 2000;278:H1345-H1351.
28. Hexeberg S, Froyland L, Asiedu DK, Demoz A, Berge RK. Tetradecylthioacetic acid reduces the amount of lipid droplets, induces megamitochondria formation and increases the fatty acid oxidation in rat heart. J Mol Cell Cardiol 1995;27:1851-1857.
29. Asiedu DK, Froyland L, Vaagenes H, Lie O, Demoz A, Berge RK. Long-term effect of tetradecylthioacetic acid: a study on plasma lipid profile and fatty acid composition and oxidation in different rat organs. Biochim Biophys Acta 1996;1300:86-96.
30. Mjøs OD. Effect of fatty acids on myocardial function and oxygen consumption in intact dogs. J Clin Invest 1971;50:1386-1389.
31. Opie LH. The Heart: Physiology, from Cell to Circulation. Philadelphia, PA: Williams and Wilkins; 2004.
32. Myrmel T, Forsdahl K, Larsen TS. Triacylglycerol metabolism in hypoxic, glucose-deprived rat cardiomyocytes. J Mol Cell Cardiol 1992;24:855-868.
33. Liu Q, Docherty JC, Rendell JC, Clanachan AS, Lopaschuk GD. High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation. J Am Coll Cardiol 2002;39:718-725.
34. Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K. Uncoupling proteins in human heart. Lancet 2004;364:1786-1788.
35. Himms Hagen J, Harper ME. Physiological role of UCP3 may be export of fatty acids from mitochondria when fatty acid oxidation predominates: an hypothesis. Exp Biol Med (Maywood) 2001;226:78-84.
36. Esteves TC, Brand MD. The reactions catalysed by the mitochondrial uncoupling proteins UCP2 and UCP3. Biochim Biophys Acta 2005;1709: 35-44.
37. Suga H. Ventricular energetics. Physiol Rev 1990;70:247- 277.